While therapeutic options remain limited, several emerging targeted therapies demonstrate promising activity in advanced chordoma, including tyrosine kinase inhibitors, brachyury vaccines, and PI3K/AKT inhibitors [15]. This evidence concerns the gene TBX1 and chordoma.